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Director: G eorge L. Card
LTD4  d ipeptidase is the en zym e that converts the m ost active leukotriene, 
LTD4, to the least active form, LTE4. The biological activity of LTD4 h a s b een  
reported to be severa l tim es higher than that of LTE4. Therefore, the nature 
and  intensity of a  leukotriene resp on se  could be influenced by the relative 
concentration of LTD4 and LTE4, which in turn, could b e determ ined by the  
relative rate of m etabolism  of LTD4 to LTE4. In undiluted, untreated hum an  
serum , inhibition of LTD4  d ipeptidase w as observed . T he specific  activity of 
LTD4  d ipeptidase in creased  on dilution of human serum . To isolate and identify 
inhibitory factor(s), s ize  exclusion chrom atographic tech n iq u es w ere em ployed. 
The inhibitory factor(s) w a s separated  from the serum  dipeptidase by 
ultrafiltration with Amicon YM-10 m em branes. The inhibitory activity in the YM- 
10 filtrate w a s stab le on prolonged (over 30  m inutes) heating at 95® C, stab le in
0 .3  M NaOH, and w as destroyed  by acid treatm ent at 0® 0  and 30® 0 .  
Ultrafiltration with YM-10, YM-3, YM-1 , and YC-05 m em branes su g g e ste d  that 
th e m olecular w eight of the inhibitor(s) w a s le ss  than 500 . B a sed  on th e se  
ob servation s and the elution volum e of the inhibitor activity from a P-2 gel 
filtration colum n, the inhibitor h as b een  tentatively identified a s  carbonate  
(bicarbonate). The LTD4 dipeptidase activity in a  50-75%  am m onium  sulfate  
saturated  fraction of serum  w a s inhibited by carbonate (bicarbonate) or 
p h osp h ate , but not by nitrate, sulfate and chloride. A maximum of 50%  
inhibition of d ipeptidase activity w as ob served  at 2 5 0  mM bicarbonate. 
C om parable concentrations of phosphate result in 100%  inhibition. The 
physiological inhibitor in serum  appeared  to be carbonate (bicarbonate). The 
relative carbonate (bicarbonate) concentration could b e  a  factor in determ ining  
the rate of LTD4  to LTE4  conversion, and therefore important in m odulating the  
leukotriene m ediated resp on se.
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CHAPTER 1 
INTRODUCTION
Arachidonic acid (5,8,11,14-eicosatetraenoic acid) is a 20-carbon 
polyunsaturated fatty acid. It is commonly present in cell membrane 
phospholipid (phosphatidylcholine, phosphatidyl-inositol, etc.) esterified 
primarily to the second carbon (C-2) position of glycerol. Release of 
arachidonic acid from the lipid pool by the action of phospholipase A  ̂ is 
mediated by different types of stimuli (57), which can be physiological or 
pathological. The released arachidonic acid has a very short half life. It is 
either metabolized by the enzyme, cyclooxygenase, to form prostaglandins 
and thromboxanes, or by lipoxygenase pathways to form leukotrienes and 
lipoxins (57), or is reincorporated into the membrane lipids (Fig. 1).
Arachidonic acid is derived primarily from two phosphlipids, 
phosphatidylinositol and phosphatidylcholine. Two enzymes, phospholipase 
C and phospholipase Ag are mainly involved in the release of arachidonic 
acid (Fig. 2). When cells are activated by stimuli, it leads to the increased 
permeability of ions across the membrane, especially a flow of ions 
from the extracellular to intracellular compartment. The resulting 
increased intracellular Ca+ concentration stimulates the cytoplasmic 
phosphatidylinositol specific phospholipase C, which acts on 
phosphatidylinositol to give inositoltriphosphate (IP3) and 
diacylglyceride (DAG) (57). DAG is acted upon by other lipases to yield a
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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Figure 1. The metabolism of arachidonic acid
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Figure 2. The release of arachidonic acid
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monoacylglyceride and arachidonic acid. IP 3  induces additional Ca^* 
mobilization from the endoplasmic reticulum to the cytoplasm, and this 
further activates phospholipase C. Protein kinase C (PKC) is the major 
enzyme activated by DAG. PKC phosphorylates a phospholipase Aj 
inhibitory protein. This phosphorylation causes inactivation of the 
inhibitory protein, resulting in increased activity of phospholipase Ag, 
which cleaves arachidonic acid from phosphatidylcholine ( 1 ).
The formation of prostaglandins and thromboxanes is initiated by the 
enzyme prostaglandin endoperoxide synthase (PES). The cyclooxygenase 
activity of the prostaglandin endoperoxide synthase can transform 
arachidonic acid and certain other polyunsaturated fatty acids into 
prostaglandins. The enzyme oxidizes arachidonic acid to yield a 15- 
hydroperoxy-9,1 1 -endoperoxide with a substituted cyclopentane ring (PGGj). 
The peroxidase activity of PES then reduces PGGg to its 15-hydroxy 
analogue (PGHg). The cyclooxgenase and peroxidase activities of PES reside 
in a single protein (51). PGHg can be converted into PGDg, PGEg, PGFg, and 
PGIg by the enzymes glutathione-S-transferase, prostaglandin endoperoxide 
E isomerase, prostaglandin endoperoxide reductase and prostaglandin 
endoperoxide I isomerase, respectively.
The formation of thromboxane Ag is catalyzed by thromboxane A 
synthase. The enzyme th a t converts prostaglandin endoperoxides to 
thromboxanes was first found in platelets (51). The physiological effects of
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
prostaglandins and thromboxanes have been studied in great detail. They 
affect nearly every system in the body and include inflammation, clotting, 
osmotic gradients and smooth muscle contraction.
The lipoxygenase pathways involve insertion of oxygen molecules a t 
5-, 12-, and 15- carbon positions of arachidonic acid by 5-, 12-, and 15- 
lipoxygenases, respectively. The platelet 12-lipoxygenase converts 
arachidonic acid to 12-S-hydroperoxyeicosa-5,8,10,14-tetraenoic add  (12-S- 
HPETE). Peroxidase activity associated with the 12-lipoxygenase 
hydrolyzes 12-HPETE into its hydroxy analogue 12-HETE. The biological 
activities of the 1 2 -lipoxygenase products include the migration of aortic 
smooth muscle cells in vitro, inhibition of collagen-induced platelet 
aggregation, inhibition of cyclooxygenase activity at high concentration, and 
the amplification of the production of LTB* (50).
The 15-lipoxygenase converts arachidonic acid to 15-hydroperoxide 
eicosatetraenoic add  (15-HPETE) and this product inactivates the enzyme 
by oxidizing a single methionine residue (44). At least two trihydroxylated 
compounds, lipoxin A (5,6,15(L)-trihydroxy-eicosa-7,9,ll,13-tetraenoic add) 
and lipoxin B (5(0),14,15 {L)-trihydroxy-eicosa-6,8,10,12-tetraenoic acid), are 
formed when hum an neutrophils are incubated with 15-HPETE and a 
caldum  ionophore. These lipoxins are another group of biologically active 
derivatives which can cause contraction of lung strips, dilation of 
microvasculature, and inhibition of natural killer cell cytotoxicity. They
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
may also play an important role in inflammation and immunity (49).
The leukotriene family is a group of biologically active molecules, 
formed by leukocytes, mast cells, macrophages, and other tissues and cells 
in response to immunological and nonimmunological stimuli. They were 
first reported in 1938 as a smooth muscle-contracting factor in lung 
perfusates and referred to as "slow reacting substance of anaphylaxis" (SRS- 
A). I t  was not until 1979 that their structures were identified and their 
physiological functions elucidated.
The enzyme 5-lipoxygenase catalyzes the lipoxygenation of 
arachidonic acid a t C-5 to initiate the synthesis of leukotrienes (23) (Fig. 3). 
Leukotriene A4  (LTA*) is a key intermediate in leukotriene biosynthesis. It 
is derived from arachidonic acid by two consecutive reactions, oxygenation 
a t C-5 followed by dehydration, both catalyzed by 6 -lipoxygenase. The 
highly unstable allylic epoxide LTA4  can be metabolized by two alternative 
pathways. Hydrolysis of LTA4 , catalyzed by LTA4  hydrolase leads to the 
formation of leukotriene B4  (LTB4 ) (50). LTB4  can be further metabolized by 
CD-hydroxydation to 20-hydroxy and 20-carboxy LTB4  (7). Alternatively, the 
addition of glutathione by a glutathione transferase leads to the peptidyl 
leukotriene, leukotriene C4  (LTC4 ) (3, 43). LTC 4  can be cleaved successively 
by peptidase enzymes to yield leukotrienes D4  (LTD4 ) and LTE4.
The cysteinyl-containing leukotrienes (LTC4, LTD4, and LTE4) are 
potent bronchoconstrictors. They increase permeability in postcapillary venules
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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Figure 3. 5-lipooxygenase pathway
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and stimulate mucus secretion (14, 43, 49). The dihydroxy derivative, LTB4 , 
which is a calcium ionophore, causes adhesion and chemotactic movement of 
leukocytes and stimulates aggregation, enzyme release, and generation of 
superoxide in neutrophils (43). LTC^, LTD^, and LTE4, which are released 
from lung tissues of asthmatic subjects on exposure to specific allergens, 
seem to play a pathophysiological role in immediate hypersensitivity 
reactions (54). All of the leukotrienes have proinflammatory effects (47).
Leukotrienes are also formed in the central nervous system (50). The 
highest production of LTC4 is found in hypothalamus and the median 
eminence. Immunohistochemical studies revealed the coexistence of LTC4  
and luteinizing hormone-releasing hormone (LHRH) in neurons in the 
median eminence. Furthermore, LTC4  caused release of luteinizing 
hormone (LH) from ra t anterior pituitary cells suggesting a neuroendocrine 
role of LTC4.
Several other functions of LTs have been identified recently. 
Investigations by Quinn et al. showed LTC4 , LTD4  and LTE 4  played a  role 
as mediators of delayed onset acute lung injury after smoke inhalation (42). 
It was also reported tha t leukotrienes contributed to the persistence of a 
hydrochloric acid induced gastric lesion (39). Leikaut and his colleagues 
found th a t cysteinyl leukotrienes enhanced growth of airway epithelial cells 
which suggested a new physiological role for the leukotrienes in the lung 
th a t links inflammation with epithelial cell proliferation (32). It was also
8
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reported th a t LTC4  decreased the activity of respiratory cilia in vitro (61).
LTC4  is converted to LTD4  by cleavage of the glutamic acid residue by 
a y-transpeptidase (Fig. 4). This enzyme has been found in ra t basophil 
leukemia cells (25), in the supernatant of PMNs (6 , 45), in human plasma 
(28) and lung (29), and in guinea pig lung tissue. The study of the 
transpeptidase in human serum in our lab and other laboratories showed 
that the metabolism of LTC4 into LTD4 was dependent on time, amount of 
enzyme present and on the substrate concentration (60). Several forms of 
the serum y-glutamyl transpeptidase have been reported and have been 
described as isoenzymes or modifications of a single gene product.
Cleavage of a glycine residue from LTD4 by dipeptidase activity 
results in the formation of LTE4. The relative activity of the y- 
transpeptidase and the LTD4  dipeptidase might have important 
physiological consequences. The dipeptidase catalyzes the conversion of the 
most active peptidyl leukotriene, LTD4, to the least active peptidyl 
leukotriene, LTE4. The pioneering work on dipeptidase was done by 
Campbell who first purified a porcine renal dipeptidase (9). Dipeptidase 
enzymes have been subsequently isolated from many different tissues and 
cells including: rat, hog (9), human (11), and monkey kidneys, sheep (10), 
ra t (22), human (29), and guinea-pig lungs, ra t liver (24), ra t basophil 
leukemia cells (25), human PMNs (36, 45, 46), and human serum (28, 60). 
Time course studies showed a relatively slow conversion of LTD4 to LTE4,
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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compared to the rate of conversion of LTC4  to LTD4  (28). Dipeptidase is 
usually found as a membrane bound enzyme. Recently, Campbell and his 
coworkers ( 1 0 ) showed tha t the protein is anchored to the lipid bilayer by a 
covalent attachm ent to phosphatidylinositol via a C-terminal glycolipid 
extension. The dipeptidase was released by the treatm ent of 
phosphatidylinositol-specific phospholipase C from Bacillus thuringiensis. 
Size exclusion chromatography (SEC)-HPLC and electrophoresis analysis 
showed the molecular weight of the enzyme is between 105,000-140,000 
daltons. The enzyme is composed by two monomers of molecular weight 
50,000 to 70,000 daltons (10). The optimal reaction condition for the 
dipeptidase activity was obtained with 1  mM of Mn^^, Co^ ,̂ or Zn^  ̂(44, 36), 
and was completely inhibited by Cû "̂  (44), bestatin (11, 40) and a renal 
dipeptidase inhibitor, cilastatin (MK0791) (27). The presence of a natural 
inhibitory effect of LTD4  conversion has been mentioned briefly by Raulf 
and coworkers (45, 46). Studies in our lab have suggested some type of 
inh ib ito rs) is present in human serum (60). The LTD4  dipeptidase activity 
in hum an serum appeared to be regulated by the amount of the inhibitors) 
ra ther than the amount of enzyme. This indicates tha t the inhibitors) in 
hum an serum may play a very important role in regulating the leukotriene 
levels in human circulation under different physiological and pathological 
conditions (60).
Further metabolism of LTE4  has been reported in several tissues.
11
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Bernstrom and his colleagues (5) reported that ra t liver homogenates can 
covert LTE 4  to acetyl-LTE^, with the acetyl group from acetyl coenzyme A. 
Acetyl-LTE^ was the major metabolite recovered in the bile (21). It was also 
found th a t the human and ra t kidneys convert the LTE^ to acetyl-LTE^ 
which was then found in the urine. LTA4  can also undergo nonenzymatic 
hydrolysis into the C-12 epimers of, 12-dihydroxy-6,8,10-trans-14-cis- 
eicosatetraenoic acid and two isomers of 5,6-dihydroxy-7,9,11,14- 
eicosatetraenoic acid (2 0 ).
Although the biological effects of LTE4  and acetyl-LTE 4  are 100-fold 
lower than that of LTD4 , they still have biological activity (48). So, the 
further metabolism of LTE* and acetyl-LTE4  resulting in complete 
term ination of the biological activity has been extensively examined (4). 
More recently, Shamhoun and his coworkers showed another route of 
degradation of LTE 4  and acetyl-LTE 4  via co-oxidation and p-oxidation which 
alters the fatty acid (16, 48). The end products formed here were 20-COOH- 
LTE 4 , 20-COOH-N-acetyl LTE4 , 18-COOH-19,20-dinor-LTE4 (dinor-LTE 4 ), 
and 16-COOH-17,18,19,20-tetranor-LTE4 (tetranor-LTE 4 ). These results 
demonstrate tha t the metabolism of leukotrienes may be a detoxification 
ra ther than an inactivation of cysteinyl-containing leukotrienes.
12
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THESIS OBJECTIVE;
The major objectives of this study were to isolate, characterize, and 
hopefully identify the factor(s) which inhibits LTD^ dipeptidase activity in 
hum an serum.
13
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CHAPTER 2 
MATERIALS AND METHODS
Materials:
HPLC Grade methanol and acetonitrile were purchased from Fisher 
Chemical, Fisher Scientific (Fair Lawn, NJ). Leukotrienes were purchased 
from Cayman Chemical (Ann Arbor, MI), and the tritium  labelled 
leukotrienes were purchased from New England Nuclear (Boston, MA). The 
resin, nucleosil 5 C18 lOOA, for reverse phase HPLC was obtained from 
Phenomenex (Torrance, CA), and the columns were generously packed by 
ChromatoChem, Inc. (Missoula, MT). YM membranes were purchased from 
Amicon Div., W.R. Grace & Co. (Danvers, MA). The Bio-Gel P-2 was firom 
Bio-Rad Laboratories (Richmond, CA). The bicinchoninic acid protein assay 
reagents were purchased from Sigma Chemicals (St. Louis, Mo). All other 
chemicals were of reagent grade and purchased from standard sources.
Methods:
1 . Collection of Human Blood and Sera:
Human blood from healthy volunteers was drawn from the cubital vein 
into heparinized or heparin-free vacutainers. The blood was set in the 30° C 
w ater bath for 30 min until the clotting was completed, and was centrifuged 
a t 2,000 rpm, a t 4° C, for 30 min. The serum was collected using a Ulti-Sep
14
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Serum Separator, and pooled. The pooled sera was divided into 1  ml 
aliquots and stored a t -70° C.
2. Separation of LTD4  Dipeptidase from the Inhibitory Factors)
Serum was mixed with 20 mM Tris-HCl buffer (pH 7.4) in a 1:50 ratio
and filtered with an Amicon Micro-ultrafiltration system using a YM-10 
membrane. The flow rate was 10 ml per hour under 40 psi nitrogen a t 5° C. 
The filtered serum was divided into 1  ml aliquots and stored a t -70° C.
3. Ammonium Sulfate Fractionation of LTD^ Dipeptidase:
The method developed by B. J. Campbell (9) was modified and used. In a 
typical preparation, 3 grams solid ammonium sulfate were added to 10 ml of 
pooled sera, mixed and allowed to stand a t 4° C for 12 hours. The 50% 
ammonium sulfate saturated sera was then centrifuged at 4,500xg for 1 
hour. The pellet was resuspended in 5 ml 20 mM Tris-HCl Buffer at pH 7.4 
and dialyzed against the same buffer for 18 hours with four changes of 
buffer. Solid ammonium sulfate was then added to the supernatant to 
result in 75% saturation. After standing a t 4° C over night, the 75% 
ammonia sulfate saturated suspension was centrifuged a t 1 0 ,0 0 0 xg for 1  
hour. The sediment was resuspended in 5 ml 20 mM Tris-HCl buffer at pH
7.4 and dialyzed as previously described. The two different fractions will be 
designated as 50% precipitate and 75% precipitate.
15
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4. Isolation and Concentration of Inhibitor by Ultrafiltration:
In a typical experiment, 50 ml pooled sera was added to an Amicon 
ultrafiltration system model 52 with a YM-10 membrane, under 40 psi 
nitrogen a t 4" C. The filtrates from several runs (about 40 ml) were pooled, 
divided to 20 ml aliquots and lyophilized. The lyophilized filtrate was 
resuspended in 1 ml triple distilled water and was designated as 20X 
concentrated inhibitor solution.
5. Purification of Inhibitor by Gel Filtration:
Size Exclusion Chromatography (SEC) was used to attem pt to further 
isolate the inhibitor. The Bio-Rad polyacrylamide gel resin P-2 was used. 
Best resolution was obtained with a 1.3 X 45 cm column using an eluent 
buffer containing 10 mM Mops and 10 mM NaCl, pH 7.4. The flow rate was 
controlled between 12-15 ml per hour, and ferritin, vitamin Bjj, and 
dinitrophenylalanine (DNP-ala) were used as the molecular weight markers. 
One ml fractions of eluate were collected with a ISCO model 1850 Fraction 
Collector and UV-absorbance was measured with a model UA-5 Absorbance/ 
Fluorescence Monitor (ISCO, INC.).
6 . Bicarbonate Determination:
BaClg, a t a final concentration of 20 mM, was added into all 1 ml- 
fractions from the P-2 column. The white precipitation of Ba(HC 0 g) 2  was
16
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monitored by absorbance reading a t a wavelength of 600 nm with a Perkin- 
Elmer Lambda 3A UV/VI8  spectrophotometer.
7. Assay of Leukotriene Dipeptidase Activity:
The reaction mixture consisted of a mixture of 100 ng synthetic unlabeled 
LTD4, tritium  labeled LTD4 0.8 pi ( 0.1 ng LTD4, specific activity: 1.8x10* 
dpm), and 100 pi enzyme (protein concentration: 27.1-60.6 pg/pl) in a 100 
mM NaCl, 5 mM CaClg, 0.1% triton, and 100 mM Mops buffer a t a pH of 
7.4. The mixture was incubated in 37® C water bath for 15 to 35 min 
depending on which enzymatic activity was being measured. The reaction 
was stopped by adding 0.5 ml cold methanol (-20° C). The mixture was then 
stored a t -70° C for a t least 1  hour prior the lipid extraction.
8 . Lipid Extraction:
Cold methanol was used to stop the reaction and extract the lipid in the 
mixture. The mixture was centrifuged a t 2,000xg for 30 min a t 4° C. The 
supernatant was transferred to a conical centrifuge tube and the residue 
was extracted with another 0.5 ml methanol. After centrifugation the 
supernatants were pooled and evaporated to dryness under vacuum at 40°
C. The samples were stored a t -70° C until HPLC analysis. All glassware 
used for the assays was silicone-treated to prevent the adherence of lipids to 
the surface, and to minimize loss of leukotreines.
17
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9. RP-HPLC Analysis:
A CIS 5 Tim 100 A nucleosil HPLC column, 4.6 X 250 mm, was used for 
reverse-phase HPLC analysis. The solvent used for isocratic eluting 
contained acetonitrile, methanol, acetate, and distilled water 
(320:200:1:479). Disodium EDAT (0.5%) was added and pH was adjusted to
5.5 w ith ammonium hydroxide. The leukotriene extract was dissolved in
0.15 ml eluting solvent and eluted from the column a t a flow rate of 1.0-1.5 
ml/min. The products of [^H] LTD^ metabolism were quantified by the 
distribution of tritium  counts in the different fractions using an in-line 
radioactivity flow detector.
18
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CHAPTERS
RESULTS
1 . LTD 4  dipeptidase inhibitor activity in human serum:
Previous experiments in our laboratory showed th a t dilution of serum 
did not result in a corresponding dilution of LTD^ dipeptidase activity. A 
typical experiment using a series of two-fold serum dilutions is shown in 
Fig. 5. The highest specific activity was usually observed a t a 1:32 dilution. 
This indicates the presence of some type of inhibitory factoHs) in the serum.
2 . Serum fractionation:
The inhibitory factor(s) was successfully separated from the LTD4  
dipeptidase by using an Amicon ultrafiltration system with a YM-10 
membrane. As shown in Fig. 6 , the LTD4 dipeptidase activity was increased 
after removing the inhibitory factor(s) by filtration, and showed an almost 
linear decrease in dipeptidase activity with serial dilution. The products of 
LTD4  formed in the presence of a 25-50% ammonium sulfate fraction and a 
50-75% ammonium sulfate serum fraction are shown in Fig. 7. Based on 
the lower amount of the unidentified metabolite produced by the 50-75% 
fraction, this preparation was used for the separated studies. Using the 
synthetic LTE4  as a substrate, it was shown tha t the unknown metabolite 
was a  product of LTE4 metabolism (Fig. 8). There was no dipeptidase 
activity in either 0-25% ammonium sulfate fraction or in the 75-100%
19
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DIPEPTIDASE SPECIFIC ACTIVITY
SERUM DILUTION STUDY
SPECIFIC
ACTIVITY
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DILUTION (1: undiluted, 6 0 .6  mg/ml)
Figure 5. Untreated serum was 2-fold series diluted with 100 mM 
Mops buffer, pH 7.4. The enzyme assay was carried out as described in 
M aterials and Methods (M&M) part 7. HPLC method described in M&M 
part 8  and 9 was used to quantify the conversion of leukotrienes. Solid line 
shows the LTD^ conversions with the dilution of the untreated serum. 
Dotted line shows the specific activities of the untreated serum with the 
dilution. The specific activity is expressed as pmol leukotriene converted 
per min per mg protein.
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AMICON MEMBRANE FILTRATION
HUMAN DIPEPTIDASE ACTIVITY
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g
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1 /321 / 1 61/81/2 1/ 41
DILUTION (1: UNDILUTED)
Figure 6 . Human serum LTD^ dipeptidase activity was separated 
from the inhibitory factoKs) by an Amicon Micro-ultrafiltration system 
using a YM-10 membrane as described in the part 2 of M&M. Then dilution 
and enzyme assay were carried as described in Fig. 5. Solid line shows the 
filtered dipeptidase activity. Dotted line shows the untreated serum.
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JIIA.
LTD4 CONTROL UTD4
B LTD4 INCUBATED W/ 50-75% 
(NH^)gSO^ PPT. FRACTION
LTE4
LTD 4
LTD4 INCUBATED W/ 25-50% 
(NH^)gSO^ PPT. FRACTION
LTD 4
Figure 7. Ammonium sulfate fractionation of serum was carried out 
as described in the part 3 of M&M. Different fractions were tested for the 
dipeptidase activity. The distribution of radioactivity counts on 
chromatograph was used to momitor the conversion of LTD^. (a) LTD^ 
control, (b) LTD4  was mainly converted to LTE4  by a dipeptidase activity in 
50-75% ammonium sulfate precipitation, (c) LTD4  was converted to an 
unknown metabolite by an enzymatic activity in the 25-50% ammonium 
sulfate precipitation fraction.
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Figure 8 . 100 ng LTE 4  was used as the substrate incubting with the 
25-50% saturated ammonium sulfate precipitation fraction. Standard LTE^ 
and metabolized LTE4 were measured a t a wavelength of 280 nm. (a) LTE4 
control, (b) Unknown metabolite with a later retention time after LTE* was 
incubated with 25-50% saturated ammonium sulfate precipitation fraction.
23
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ammonia sulfate supernatant.
3. Optimal conditions for LTD4  dipeptidase activity:
Fig. 9 shows the time course study of the LTD* dipeptidase activity in 
the 50-75% saturated ammonium sulfate fraction. Under this assay 
condition, over 90% of the synthetic LTD* was converted after 50 min 
incubation. The influence of different cations is shown in Fig. 10. The 
enzyme was about 30% inhibited by 20 mM EDTA and 10 mM EGTA, and 
was activated by 10 mM Ca^* and 2.9 mM Mn̂ "̂ . Fig. 11, 12, and 13 show 
th a t optimal activity was obtained with 1 0 0  mM NaCl and 5 mM CaClj, 
which both are close to the physiological concentration in human serum.
4. Separation of the inhibitory factors) from serum by ultrafiltration:
The Amicon ultrafiltration system with the YM-10 membrane was 
used to separate the LTD* dipeptidase inhibitory factor(s) from the serum as 
described in m aterials and methods. After lyophilization, the filtrate was 
resuspended in a volume of 20 times concentrated (20X). The addition of 
the concentrated inhibitor(s) to the dipeptidase assay mixture resulted in 
the inhibition of LTD* dipeptidase action (Table 1).
5. Characterization of the inhibitor:
The concentrated YM-10 filtrate was incubated a t 95° C for 30 min 
and assayed for inhibitory activity. The inhibitory activity was not 
destroyed. The concentrated YM-10 filtrate (20X) was stable in 0.3 N 
NaOH (20 pi 2 N NaOH in 100 pi concentrated filtrate, 20X), whereas the
24
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ENZYME: TIME COURSE STUDY
S 0 % -7 5 %  AMMONIUM SULFATE PPT.
1 0 0
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A - A -  LTE45 0I
O
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0  6 
0 5 0 100
INCUBATION TIME (min)
Figure 9. LTD^ Dipeptidase of human serum incubated with LTD^ for 
various incubation period. Same assay conditions were used as described in
Fig. 5.
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EFFECT O F IONS ON DIPEPTIDASE
CATIONS AND CHELATORS
1 0 0
1
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LTD4
J LTD4
CONVERTED
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SAMPLE
8 9 10
Figure 10. Different cations and chelators were added to observe their 
effects on the dipeptidase. Standard enzyme assays as described in Fig. 5. 
was used. Different cation concentrations were added based on their 
physilogical concentrations. 1. Buffer control. 2 . Enzyme control. 3. EDTA 
(20 mM). 4 . EGTA (10 mM). 5. Ca^+ (10 mM). 6 . Mg^+ (4 mM). 7. Fe^" 
(0.084 mM). 8 . Mn^* (2.9 mM). 9. Zn"+ (0.44 mM). 1 0 . Cu"+ (0.071 mM).
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OPTIMAL IONIC CONCENTRATION
— SODIUM CONCENTRATION STUDY
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—+ — LTD4
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SODIUM CONCENTRATION (mM)
Figure 1 1 . The influence of NaCl concentration on LTD4  dipeptidas 
activity was studied by adding different NaCI concentrations into the 
standard enzyme assays.
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OPTIMAL IONIC CONCENTRATION
— CALCIUM CONCENTRATION STUDY
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Figure 12. The influence of CaClg concentration on LTD^ dipeptidase 
activity was studied by adding diflferent concentration of Calcium into the 
standard enzyme assays.
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OPTIMAL IONIC CONCENTRATION
THE EFFECT OF SODIUM AND CALCIUM
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Figure 13. Optimal condition for dipeptidase activity was achieved by 
adding sodium chloride and Calcium chloride into the reaction mixture. 1. 
Buffer control. 2. Enzyme control. 3. 100 mM NaCl 4. 5 mM CaClg. 5. 
1 0 0  mM N ad + 5 mM CaClg.
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TABLE 1. THE DIPEPTIDASE INHIBITION PROPERTIES
OF YM-10 FILTRATE
SAMPLES
W/ YM- 1 0  FILTRATE 
% OF LTD. CONVERSION
W/O YM-10 FILTRATE 
% OF LTD. CONVERSION
1 17.47 79.90
2 13.91 83.84
3 18.34 83.50
4 21.04 8 6 . 2 0
5 17.71 84.86
6 17.47 86.36
X±SD,n= 6 17.66±2.08% 84.11±2.17%
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Figure 14. The separation of LTD4  Dipeptidase inhibitor by Bio-Rad 
gel P-2 Column was described in part 5 of M&M. (a) Molecular weight 
m arkers control: peak 1 , ferritin; peak 2, VitB^g; peak 3, DNP-ala. (b) 
Concentrated inhibitor from YM-10 filtrate (2 0 X). The inhibition was 
recovered from 49 to 60 ml with a pH range from 8  to 8.5. (c) Bicarbonate 
with the MW markers.
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IDENTIFICATION OF INHIBITOR
COMPARISON OF THE RETENTION TIME 
-  pH   ABSORBANCE
i
9 2 .40
8 1.20
0.007
655 545
o0(O
1
i  
I
ELUTION VOLUMNE (ml)
Figure 15. Comparison of retention time of synthetic bicarbonate and 
LTD 4  Dipeptidase Inhibitor from Serum. As described in part 6  of M&M, 
two indicators were mainly measured: pH and carbonate (bicarbonate). 
Sohd line: pH of concentrated YM-10 filtrate eluted from P-2 column. 
Dotted line: Absorbance of BaCHCOglj precipitation formed by synthetic 
bicarbonate eluted from P-2 column and BaClj added.
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inhibitory activity was destroyed in 0.3 N HCl (20 jil 2N HCl in 1 0 0  pi 
concentrated filtrate, 20X). The inhibitory effect was eliminated by treating 
with 0.3 N HCl a t either 0"C or a t 65”C for 30 min (Fig. 17).
Concentrated filtrate from the YM-10 membranes was filtered with 
YM-3, YM-1 , and YC-05 membranes. Inhibitory activity was recovered in 
the filtrate from each of these membranes which suggested a molecular 
weight of less than 500 (Fig. 16). Elution from the P-2 gel filtration column, 
however, suggested a molecular weight of about 800-1000 (Fig. 14B).
6 . Purification of inhibitory factor(s) by gel filtration:
The inhibitor(s) was eluted from a Bio-Rad gel P - 2  column with a 10 
mM NaCl, 10 mM Mops buffer pH a t 7.4. As shown in Fig. 14B, the 
inhibitory factorfs) was recovered from the P-2 column in fractions fi*om 49 
ml to 60 ml. The retention time of the inhibitory factor(s) from the P-2 
column corresponds to a molecular weight around 800-1,000 based on 
internal molecular weight markers vitamin (MW 1,355) and DNP-ala 
(MW 255) (Fig. 14A). The pH of the 49th ml-60th ml fractions was 8.0-8.4 
compared to 7.0-7.4 for all other fractions (Fig. 15). The pH of all 
concentrated fractions was adjusted to 7.4 for the enzyme inhibitor assay.
7. Identification of inhibitor(s):
The in h ib ito rs) was heat stable, acid labile, and resulted in an 
increase in pH when concentrated. Based on these observations we 
suspected th a t the inhibitors) might be bicarbonate. This did not
33
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correspond to the expected elution volume from the P-2 column. The 
apparent contradiction was solved when analytical grade sodium 
bicarbonate was run through the P-2 column and the same retention time 
was obtained as th a t of the inhibit activity and high pH of the concentrated 
filtrate, 20X (Fig. 14, 15). The bicarbonate elution was qualitatively 
monitored by adding BaCIj resulting in a production of white precipitate.
8 . Inhibitory activities of bicarbonate and other anions:
The effect of different anions is shown in Fig. 18. The inhibitory 
activity was found for bicarbonate and phosphate, whereas no inhibition 
was observed with sulfate or nitrate. Fig. 19 and 20 show that the 
inhibitory activity of carbonate and phosphate was dose dependent. The 
maximum inhibition caused by bicarbonate (250 mM) was about 50%, while 
th a t of the phosphate (400 mM) was 100%.
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INHIBITOR SIZE DETERMINATION
AMICON MEMBRANE YM 10  -  0 5
1 0 0
LTD4
L..,, I LTE4
UNKNOWN
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MW CUTOFF (1 0 ,0 0 0 -5 0 0 )
Figure 16. Amicon membranes were used to determine the Molecular 
Weight of LTD4  dipeptidase inhibitor. 100 pi of 20X inhibitor solution 
passed different membranes were added to standard enzyme assays. 
Inhibition was observed in all size of membrans used. 1 . Buffer control. 2. 
Enzyme control. 3. YM-10. 4. YM-3. 5. YM-1 . 6 . YC-05.
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Figure 17. 2 0 X Inhibitor solution was pretreated with 0.4 N HCl 
under heating and non-heating conditions. The inhibitory activity was 
eliminated by the acid. 1. Buffer control. 2. Enzyme control. 3. Inhibitor 
control. 4. Inhibitor with 0.4 M HCl on ice. 5. Inhibitor is heated a t 65“ C 
for 30 min with presence of 0.4 M HCl. 6 . NaCl control. 7. Salt+inhibitor 
control.
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INHIBITION OF DIPEPTIDASE
THE EFFECTS OF ANIONS
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Figure 18. Inhibition of anions on LTD^ dipeptidase activity was 
assayed by addeding different anions concentration into standard enzyme 
assay. 1. Buffer control. 2. Enzyme control. 3. Bicarbonate (lOOmM). 4. 
Phosphate (lOOmM). 5. Sulfate (lOOmM). 6 . N itrate (200mM).
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INHIBITION O F DIPEPTIDASE
THE EFFECT OF BICARBONATE
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Figure 19. Different amount of bicarbonate was incubated with 50- 
75% ammonium sulfate saturated precipitation fractionation of hum an 
serum. A 50% inhibition was observed when 250 mM bicarbonate was 
added.
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INHIBITION OF DIPEPTIDASE
THE EFFECT OF PHOSPHATE
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Figure 20. Different amount of phosphate was incubated with 50- 
75% ammonium sulfate saturated precipitation fractionation, A 100% 
inhibition was observed when 400 mm phosphate was added.
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CHAPTER 4 
DISCUSSION
The peptidyl leukotrienes of the 5-lipoxygenase pathway of 
arachidonic acid metabolism have been identified as the active ingredients 
of the substances collectively known as slow-reacting substance of 
anaphylaxis (SRS-A). The leukotrienes rapidly gained substantial attention 
when the potency of their biological activities on certain cells and organs 
were found to exceed that of many traditional autocoids such as histamine, 
catecholamines, kinins, and prostaglandins (8 ). Of particular importance is 
the action of the leukotrienes on the pathological processes of allergic 
reactions, endotoxemias, tissue injury, and inflammatory responses. 
Identification and characterization of the receptors of leukotrienes and their 
natural and synthetic inhibitors have been extensively studied (18, 26, 35, 
45, 55, 60, 63). Such studies were undertaken to try to develop specific 
pharmaceutical agents which may prevent, moderate, or reverse 
leukotriene-dependent reactions, and to use such therapeutic reagents to 
trea t leukotriene related diseases.
LTD 4  dipeptidase is the enzyme which converts the most active 
leukotriene, LTD^, to the least active form, LTE^. The biological activity of 
LTD4  has been reported to be 25 to 100 times higher than tha t of LTE 4  (19, 
48, 58). It is probable, therefore, tha t the nature and intensity of the
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response would be influenced by the relative concentrations of LTC*, LTD4 , 
and LTE 4  which, in turn, could be determined by the relative rates of 
metabolism of LTC* to LTD4 and LTD4 to LTE4. The marked increase in the 
specific activity of the LTD4  dipeptidase in the serum dilution experiments 
(Fig. 5) suggested tha t the enzyme activity is determined by inhibitor 
concentration ra ther than enzyme concentration. Since the first dipeptidase 
was isolated from porcine kidney in 1969 (9), enzymes from several different 
species and tissues have been isolated and characterized (10, 11, 17, 22, 27- 
29). Likewise, several dipeptidase inhibitors have been also studied. 
Generally, bestatin ( 1 0 , 1 1 , 40) and D-penicillamine (24) cause 
noncompetitive inhibition of dipeptidase, whereas cilastatin (27), 
dithiothreitol, and chloroacetyldehydrophenylalanine are competitive 
inhibitors of the enzyme (10, 11). Inorganic phosphate, ATP, ADP, and 
AMP have also been reported to inhibit the dipeptidase (9). Some divalent 
metal ions may also play important roles in dipeptidase metabolism, since 
the m etal chelator, o-phenanthroline, can inhibit the dipeptidase activity, 
and the inhibition can be reversed by adding divalent metal ions such as 
Cô "̂ , Mn^*, and Zn^\ This also suggests that the dipeptidase from certain 
sources may be a metalloenzyme (36). None of these dipeptidase inhibitors 
seems a likely candidate for the natural inhibitor in serum (Table. 2)
The inhibition of the dipeptidase in undiluted human serum was suggested 
by the observations of Roller et al (28). They assayed the y-transpeptidase
41
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TABLE 2. COMPARISON OF THE LTD^ DIPEPTIDASE 
SESENSITIVITY TO BESTATIN AND CILASTATIN
DIPEPTIDAES INHIBITOR CONCENTRATION (mM) INHIBITION
HUMAN SERUM BESTATIN
CILASTATIN
0.001
0.005
0.05
0.001
0.005
0.05
0
0
50%
0
0
50%
SHEEP LUNG'*°* BESTATIN
CILASTATIN
0.001
0.005
0.001
0.005
6%
41%
48%
100%
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in  undiluted hum an serum but used a 1:50 dilution for the dipeptidase 
assay. A similar phenomenon was observed by Foster and his coworkers 
(17) in their studies of LTC^ metabolism in the anesthetized rat. 
Intravenously injected LTC4  was rapidly converted to LTD4 , while the 
conversion of LTD 4  to LTE4  was considerably slower. The results of our 
studies suggested to us tha t carbonate (bicarbonate) is responsible for the 
LTD4 dipeptidase inhibitory activity in normal serum. The dipeptidase 
activity did not decrease until the serum was diluted 32 fold. After 
filtration with a YM- 1 0  membrane, the bicarbonate and phosphate were 
removed in the filtrate, and the retained enzyme activity decreased with 
dilution as expected. Inhibitions caused by bicarbonate and phosphate are 
dose dependent. Bicarbonate is a more likely the main inhibitor in serum 
than phosphate because of its higher physiological concentration (25 mM, 
for bicarbonate, vs. 2 mM for phosphate). The finding th a t inorganic 
phosphate inhibits hum an serum LTD4 dipeptidase is consistent with the 
results of Campbell and his coworkers who identified inorganic phosphate 
as an inhibitor for porcine renal dipeptidase (9). Our studies represent the 
first time that bicarbonate was identified as a natural inhibitor of LTD4 
dipeptidase in hum an serum. The experiments in our lab also showed that 
LTD4 dipeptidase activity in human serum is less sensitive than previously 
reported inhibitors , cilastatin and bestatin (Table. 2). Additionally, the 
dipeptidase activity in hum an serum is not dependent on divalent metal
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ions, and was not specifically activated by Cô *, M n-\ and Zn^\
Furtherm ore it was interesting to find that higher concentrations of 
divalent ions (5mM), which can precipitate bicarbonate, would increase the 
dipeptidase activity. Addition of the chelator, EDTA, restores the inhibitory 
effect. These results suggest that it was the depletion of bicarbonate by the 
divalent ions which increased the dipeptidase activity in human serum 
ra ther than  a stimulation of enzymatic activity.
Asthma is a disease characterized by episodic bronchoconstriction, 
hypersecretion of mucus, and inflammation of airways. It was estimated 
th a t approximately five percent of adults and seven to ten percent of 
children in the United States have the disorder (56). Evidence suggests 
th a t the 5-lipoxygease pathway metabolites of arachidonic acid, especially 
the peptidyl leukotrienes (LTD4 , LTC4 , LTE4 ), have a very im portant role in 
mediating the physiologic events in asthma. Schwartzberg and his 
colleagues observed a 50-fold elevation of LTC4  levels in children with an 
acute asthm a attacks (52-54). An increased level of leukotrienes was found 
in brochoalveolar lavage fluid from atopic asthmatics (62). Radeau and his 
coworkers reported an enhanced arachidonic acid metabolism in asthm a 
patients (43). The elevated level of leukotrienes may be a result of either 
increased release from the inflammatory cells (eosinophiles, macrophage 
etc.) or inhibition of leukotriene degradation by the leukotriene metabolizing 
enzymes or both. Our experimental data showed that bicarbonate is one of
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the inhibitory factors in human serum. Because it is inhibitory a t 
physiological concentrations, it may play a major regulatory role in 
regulating the LTD4  dipeptidase activity in human serum.
Bicarbonate is the major component of the carbonic/bicarbonate 
buffering system in human circulation. The system is defined by the 
Henderson-Hasselbach equation: pH = 6 . 1  + log ([HCO3  MH 2 CO3 ]). Mainly 
two organs and one enzyme are involved in regulating the carbonic 
acid/bicarbonate buffer system. The carbon dioxide produced by aerobic 
metabolism of different tissues is transported to the lung and exhaled. The 
rate of respiration and COg/Og exchange capacity of the lung is one method 
contributing to the regulation this system. The kidneys are the second 
contributor in regulating the buffer system. The bicarbonate is reabsorbed 
when its serum concentration is less than 26 mEq/L, and it is excreted in 
the urine if its serum concentration is greater than 26 mEq/L. Bicarbonate 
is reabsorbed in the proximal and distal tubule, with 85 to 90 percent 
reabsorbed proximally, and 10 to 15 per cent distally. The enzyme involved 
in regulating this buffer system is carbonic anhydrase. This enzyme exists 
a t a high concentration in red blood cells, and on the luminal surface of 
proximal tubule cells in kidneys. It catalyzes the reversible reaction: COg + 
HgO = HgCOa = 4 . H CO 3 . The first reaction rate, catalyzed by carbonic
anhydrase, is several hundred times higher than  that without the enzyme. 
The second reaction occurs rapidly without an enzyme. The COg produced
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by the aerobic metabolic process diffuses from cells into tissue capillaries 
and enters red blood cells. The carbonic anhydrase in the red blood cells 
converts the COg into HCO3 . The newly produced bicarbonate diffuses into 
plasm a because cell membranes are much more permeable to negatively 
charged anions (e.g. HCO3*, Cl ) than to positively charged cations (e.g. K*, 
H^). The electrostatic difference across the cell membrane created by the 
movement of HCO 3  can be neutralized by the movement of Cl into the red 
blood cells, which is called the chloride shift". This is the major source of 
bicarbonate for the carbonic acid/bicarbonate buffer system. The reverse 
reaction is carried out when bicarbonate is reabsorbed in the kidney by the 
carbonic anhydrase on the surface of proximal tubule cells. Under normal 
physiological conditions, when a fixed acid is produced in extracellular 
circulation, it can be buffered by bicarbonate. The COg produced is exhaled 
from lung. When an airway obstruction happens, the Og/COg exchange is 
partially or completely dysfunctional, the COg produced by the human body 
will be retained in the tissue capillaries. The retained COg may accelerate 
the enzymatic conversion to bicarbonate, which is catalyzed by carbonic 
anhydrase. This study suggests that increased bicarbonate levels might 
inhibit the LTD4  dipeptidase activity, causing a higher concentration of the 
more biologically active leukotrienes. The elevated LTD4 may enhance the 
inflammatory process, mediate the immediate hypersensitivity reaction, and 
cause more severe clinical symptoms and manifestations. Previous
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researchers have also shown that there are LTC4  and LTD4  receptors on the 
surface of human red blood cells (18). No physiological functions of these 
receptors have been identified, and it has been confirmed tha t there are no 
leukotriene metabolizing enzymes in the red blood cells. It would be 
interesting to determine the effect of LTD4  on carbonate metabolism in 
erythrocytes. Under asthmatic conditions, bicarbonate levels in the blood 
should increase because of oxygen deprivation. This may result in increased 
COg and HCO3. and consequently decreased detoxification of LTD4  by serum 
dipeptidase. Modulating the effects of leukotriene may be proposed as 
follows. At elevated levels, leukotrienes may bind to the receptors on red 
blood cells. This binding may result in the generation of a second 
messenger, such as cAMP, which would modulate and ultimately inhibite 
the activity of carbonic anhydrase. Decreased carbonic anhydrase activity 
would result in decreased bicarbonate levels, leading to increased 
di peptidase activity. As leukotriene levels fall on detoxification by 
dipeptidase, decreased generation of the second messenger would occur, 
carbonic anhydrase activity would increase and serum bicarbonate levels 
would return  to normal. These processes would be initiated by the 
obstruction and relief of the obstruction of the airways. The discovery of a 
possible role for bicarbonate as the inhibitor of leukotriene metabolism may 
lead to the development of new therapeutic agents in treating leukotriene 
associated diseases, especially anti-asthma drugs.
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The major phosphate stores in humans reside intracellularly in cell 
cytoplasm. The organic phosphate is incorporated into lipid as 
phospholipids which compose the cell membranes. Phosphorous is mainly 
found as a bone component and exists at relativly low levels as phosphate 
in the extracellular circulation. A phosphate buffering system also plays a 
modest role in regulating the pH of blood. Three buffer pairs, H^PO/ 
/H 3 PO 4 , HPO^^ /HgPO^, and PO/VHPO^^', could potentially be formed.
Under the physiological conditions a t pH 7.4, the HPO^^VHgPO/ system with 
a pK of 6 . 8  is most important. At pH 7.4, there will be four molecules of 
HPO^^ for every molecule of H^PO/. Experimental data indicated tha t 
inhibition by phosphate occurs a t a concentration almost 2 0  times higher 
than  normal physiological levels (2 mM). This suggests th a t the phosphate 
inhibition of LTD4 dipeptidase may play a minor part in regulating the 
leukotriene levels in serum, except under extreme conditions. High 
concentrations of intracellular phosphate can be released into a lesion, and 
could cause a limited and localized inhibitory effects. As demonstrated by 
Campbell and his coworkers (9), ATP, ADP, and AMP showed some 
inhibition in hog renal dipeptidase. The phosphate groups on the nucleotide 
may explain the inhibition, and the adenosine with most phosphate residues 
causes the stronger inhibition, such that, ATP is more inhibitory than  ADP 
(ATP>ADP>AMP). Further research may be carried out to reveal the 
physiologic functions of intracellular phosphate, organic phosphate of
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phospholipids, and phosphorous in bone, in the regulation of leukotriene 
metabolism.
An unknown leukotriene metabolite was recovered when the 25-50% 
ammonium sulfate precipitated human serum was incubated with LTD^ or 
LTE 4  (Fig. 7, 8 ). Our experimental data demonstrated this unknown 
metabolite to be enzymatically produced from LTE4. Reverse phase HPLC 
analysis showed the retention time of the unknown metabolite is about 3 - 4  
min la ter than th a t of LTE4. This separation using a reverse phase is based 
on both of the polarity and size of the compound. This indicates th a t the 
unknown metabolite is less polar and perhaps has a relatively lower 
molecular weight than that of LTE4. Previous studies showed LTE4 can be 
converted into several different metabolites.
Acétylation of LTE4 by acetylase in liver and kidney converts LTE4 to 
N-acetyl-LTE* (5). This compound is mainly found in the bile and urine. 
HPLC analysis using different solvent systems showed this metabolite had 
an earlier elution time, which indicates the compound has a higher polarity 
than  th a t of LTE4. LTF4 is derived from LTE4 by conjugating LTE4 and y- 
glutamyl amino acids (2). The reaction is achieved by incubating LTE4 with 
y-glutamyl transpeptidase and glutathione. HPLC analysis showed the 
compound has a very high polarity and a very early retention time,
compared to that of LTE4.
LTG4 is the derivative of a transamination reaction catalyzed by
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cysteine conjugate aminotransferase (59). The enzyme is found in kidney 
and liver, but not in the lung or leukocytes. HPLC analysis showed a much 
later retention time of the compound compared to that of LTE4.
Other LTE 4  metabolites include co-hydroxy LTE 4  (4), LTE^ sulfoxide 
and 6 -trans LTB* (31). All these compounds have higher polarity than that 
of LTE 4  and can be excluded. Determination of the chemical structure and 
physiological functions of the unknown metabolite could be very crucial in 
studying the metabolism of peptidyl leukotrienes. This metabolite could be 
a completely inactivated form of the biologically active peptidyl leukotrienes. 
F urther characterization of the unknown metabolite is currently in 
progress.
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CHAPTER 5 
SUMMARY
Peptidyl leukotrienes are a group of biological active metabolites from 
the 5-lipoxygenase pathway of arachidonic acid. The rate of degradation of 
the leukotrienes is controlled by their specific metabolic enzymes as well as 
the enzyme inhibitors. Isolation, identification and characterization of 
natu ra l and synthetic inhibitors may provide a novel direction in preventing 
and treating some leukotriene-associated disease. Towards this goal, 
several results achieved in this study are as follow;
1 . Bicarbonate was isolated and identified as the major inhibitory 
factor of LTD* dipeptidase in human serum, LTD* dipeptidase activity from 
hum an serum was 50% inhibited in 250 mM bicarbonate.
2. Phosphate was the other leukotriene D* dipeptidase inhibitor 
which was found in serum. It may play a modest part of the inhibition as 
phosphate levels needed for inhibition are almost 2 0  times higher than  that 
of the physiological condition.
3 . The serum  LTD* dipeptidase activity was fractionated with 
ammonium sulfate. It was found that the dipeptidase activity was in the 
50-75% ammonium sulfate precipitation fraction. The optimal enzymatic 
activity was obtained a t pH 7.4 with 5 mM CaClg, 100 mM NaCl in the 
assay mixture.
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4. An unknown metabolite of LTE 4  was formed when either LTD4  or 
LTE 4  was incubated with the 25-50% ammonia sulfate precipitated fraction 
of serum. Reverse phase HPLC analysis indicates the unknown leukotriene 
metabolite may have a lower molecular weight and polarity than th a t of 
LTE4.
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